Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,477.16
(
-1.74%
)
US TECH 100
23,031.60
(
-2.05%
)
Dow Jones
45,960.11
(
-1.01%
)
Brent Oil
102.34
(
1.65%
)
Bitcoin
68,580.00
(
-0.30%
)
News Focus
News Focus
Post# of 257295
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122815
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 202527

Monday, 07/11/2016 9:07:18 PM

Monday, July 11, 2016 9:07:18 PM

Post# of 257295
EGRX addendum—MDCO’s Orange Book patents on Angiomax (which the CAFC found valid today) run until Jan 2029:

http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=020873&Product_No=001&table1=OB_Rx

Angiomax sold about $600M per annum in the US before it initially went generic; so, now that MDCO’s patents have been found valid after all, Kangio, which has several advantages relative to Angiomax, represents a pretty big market opportunity for EGRX.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today